Targeted Agent Use in Cancer Patients at the End of Life

Overview

Journal J Pain Symptom Manage

Publisher Elsevier

Specialties Critical Care
Pharmacology
Psychiatry

Date 2012 Dec 6

PMID 23211648

Citations 25

Authors

David Hui

Meghan Sri Karuturi

Kimberson Cochien Tanco

Jung Hye Kwon

Sun-Hyun Kim

Tao Zhang

Jung Hun Kang

Gary Chisholm

Eduardo Bruera

Affiliations

Soon will be listed here.

Abstract

Context: The use of targeted therapy at the end of life has not been well characterized.

Objectives: To determine the frequency and predictors of targeted therapy use in the last days of life.

Methods: All adult patients residing in the Houston area who died of advanced cancer between September 1, 2009 and February 28, 2010 and had contact with our institution within the last three months of life were included. We collected baseline demographics and data on chemotherapy and targeted agents.

Results: Eight hundred sixteen patients were included: average age 62 years (range 21-97), female 48% and white 61%. The median interval between the last treatment and death was 47 (interquartile range [IQR] 21-97) days for targeted agents and 57 (IQR 26-118) days for chemotherapeutic agents. Within the last 30 days of life, 116 (14%) patients received targeted agents and 147 (18%) received chemotherapy. Regimens given in the last 30 days of life included a median of one (IQR 1-2) chemotherapeutic or targeted agent and 43 (5%) patients receiving targeted agents had concurrent chemotherapy. The most common targeted agents in the last 30 days of life were erlotinib (n = 25), bevacizumab (n = 20), rituximab (n = 11), gemtuzumab (n = 8), and temsirolimus (n = 8). On multivariate analysis, younger age (odds ratio [OR] 0.98 per year, P = 0.01), hematologic malignancy (OR = 6.1, P < 0.001), and lung malignancy (OR = 2.6, P = 0.05) were associated with increased targeted agent use in the last 30 days of life.

Conclusion: Targeted agents were used as often as chemotherapy at the end of life, particularly among younger patients and those with hematologic malignancies. Guidelines on targeted therapy use at the end of life are needed.

Citing Articles

Cost of Hospitalization Associated with Inpatient Goals-of-Care Program Implementation at a Comprehensive Cancer Center: A Propensity Score Analysis.

Hui D, Huang Y, Andersen C, Cassel B, Nortje N, George M Cancers (Basel). 2024; 16(7).

PMID: 38610994 PMC: 11010830. DOI: 10.3390/cancers16071316.

Systemic Anticancer Treatment Near the End of Life: a Narrative Literature Review.

Geyer T, Le N, Groissenberger I, Jutz F, Tschurlovich L, Kreye G Curr Treat Options Oncol. 2023; 24(10):1328-1350.

PMID: 37501037 PMC: 10547806. DOI: 10.1007/s11864-023-01115-x.

Public Health and Palliative Care.

Cross S, Kavalieratos D Clin Geriatr Med. 2023; 39(3):395-406.

PMID: 37385691 PMC: 10571066. DOI: 10.1016/j.cger.2023.04.003.

Differences in ICU Outcomes According to the Type of Anticancer Drug in Lung Cancer Patients.

Hong Y, Hong J, Park J Front Med (Lausanne). 2022; 9:824266.

PMID: 35237632 PMC: 8882653. DOI: 10.3389/fmed.2022.824266.

Predictors of the final place of care of patients with advanced cancer receiving integrated home-based palliative care: a retrospective cohort study.

Tay R, Choo R, Ong W, Hum A BMC Palliat Care. 2021; 20(1):164.

PMID: 34663303 PMC: 8522009. DOI: 10.1186/s12904-021-00865-5.

References

Tang S, Wu S, Hung Y, Chen J, Huang E, Liu T . Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006. J Clin Oncol. 2009; 27(27):4613-8. DOI: 10.1200/JCO.2008.20.5096. View

de Bono J, Ashworth A . Translating cancer research into targeted therapeutics. Nature. 2010; 467(7315):543-9. DOI: 10.1038/nature09339. View

Hui D, Elsayem A, Li Z, De La Cruz M, Palmer J, Bruera E . Antineoplastic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model. Cancer. 2010; 116(8):2036-43. PMC: 2854875. DOI: 10.1002/cncr.24942. View

Hui D, Kilgore K, Nguyen L, Hall S, Fajardo J, Cox-Miller T . The accuracy of probabilistic versus temporal clinician prediction of survival for patients with advanced cancer: a preliminary report. Oncologist. 2011; 16(11):1642-8. PMC: 3233300. DOI: 10.1634/theoncologist.2011-0173. View

Hui D, Elsayem A, Palla S, De La Cruz M, Li Z, Yennurajalingam S . Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center. J Palliat Med. 2009; 13(1):49-57. PMC: 2883821. DOI: 10.1089/jpm.2009.0166. View

Setoguchi S, Earle C, Glynn R, Stedman M, Polinski J, Corcoran C . Comparison of prospective and retrospective indicators of the quality of end-of-life cancer care. J Clin Oncol. 2008; 26(35):5671-8. PMC: 2650390. DOI: 10.1200/JCO.2008.16.3956. View

Galimont-Collen A, Vos L, Lavrijsen A, Ouwerkerk J, Gelderblom H . Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007; 43(5):845-51. DOI: 10.1016/j.ejca.2006.11.016. View

Cheng W, Willey J, Palmer J, Zhang T, Bruera E . Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med. 2005; 8(5):1025-32. DOI: 10.1089/jpm.2005.8.1025. View

Soefje S, Karnad A, Brenner A . Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol. 2011; 6(2):125-9. DOI: 10.1007/s11523-011-0174-9. View

10.

Bruera E, Russell N, Sweeney C, Fisch M, Palmer J . Place of death and its predictors for local patients registered at a comprehensive cancer center. J Clin Oncol. 2002; 20(8):2127-33. DOI: 10.1200/JCO.2002.08.138. View

11.

Grunfeld E, Ramirez A, Maher E, Peach D, Young T, Albery I . Chemotherapy for advanced breast cancer: what influences oncologists' decision-making?. Br J Cancer. 2001; 84(9):1172-8. PMC: 2363889. DOI: 10.1054/bjoc.2001.1733. View

12.

Grunfeld E, Maher E, Browne S, Ward P, Young T, Vivat B . Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. J Clin Oncol. 2006; 24(7):1090-8. DOI: 10.1200/JCO.2005.01.9208. View

13.

Harrington S, Smith T . The role of chemotherapy at the end of life: "when is enough, enough?". JAMA. 2008; 299(22):2667-78. PMC: 3099412. DOI: 10.1001/jama.299.22.2667. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Earle C, Park E, Lai B, Weeks J, Ayanian J, Block S . Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003; 21(6):1133-8. DOI: 10.1200/JCO.2003.03.059. View

16.

Daher I, Yeh E . Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med. 2008; 5(12):797-805. DOI: 10.1038/ncpcardio1375. View

17.

Hui D, Con A, Christie G, Hawley P . Goals of care and end-of-life decision making for hospitalized patients at a canadian tertiary care cancer center. J Pain Symptom Manage. 2009; 38(6):871-81. DOI: 10.1016/j.jpainsymman.2009.05.017. View

18.

Boers-Doets C, Epstein J, Raber-Durlacher J, Ouwerkerk J, Logan R, Brakenhoff J . Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist. 2011; 17(1):135-44. PMC: 3267813. DOI: 10.1634/theoncologist.2011-0111. View

19.

Torino F, Maria Corsello S, Longo R, Barnabei A, Gasparini G . Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009; 6(4):219-28. DOI: 10.1038/nrclinonc.2009.4. View

20.

Earle C, Neville B, Landrum M, Ayanian J, Block S, Weeks J . Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004; 22(2):315-21. DOI: 10.1200/JCO.2004.08.136. View